联邦限制抗凝血灭鼠剂后,美国毒物中心报告的溴甲灵灭鼠剂暴露的医学结局
该回顾性观察研究分析2008年1月1日至2017年12月31日美国毒物中心国家毒物数据系统(NPDS)中单物质溴甲灵摄入并随访至已知医学结局的病例,共纳入2674例暴露。其中2227例(83.28%)为儿童(16天至12岁),该人群中2143例(96.38%)无效应,74例(3.32%)轻微效应,10例(0.45%)中度效应,无严重临床效应或死亡。391例年龄大于12岁患者(13至94岁)中,257例(65.73%)无效应,100例(25.58%)轻微效应,23例(5.88%)中度效应,9例(2.30%)严重效应,2例(0.51%)死亡;故意摄入者中1例(0.25%)死亡、4例(1.02%)严重效应。作者指出数据集存在回顾性、依赖来电信息、选择偏倚、信息偏倚和编码错误等局限,且可能有一或两例归因于溴甲灵的死亡实际并非由溴甲灵所致。
要点
- 儿童(16天至12岁)溴甲灵暴露2227例中,96.38%(2143例)无效应,3.32%(74例)轻微效应,0.45%(10例)中度效应,无严重效应或死亡。
- 成人(13至94岁)溴甲灵暴露391例中,65.73%(257例)无效应,25.58%(100例)轻微效应,5.88%(23例)中度效应,2.30%(9例)严重效应,0.51%(2例)死亡。
- 成人故意摄入者中记录到1例(0.25%)死亡和4例(1.02%)严重效应,但一例故意摄入死亡病例的细节提示可能误编码为长效抗凝血灭鼠剂。
- 作者指出该数据集存在回顾性、依赖来电信息、选择偏倚、信息偏倚和编码错误等局限,且可能有一或两例归因于溴甲灵的死亡并非由溴甲灵所致。
- 溴甲灵无解毒剂,人类毒性特征尚不明确;暴露后记录到癫痫发作、死亡及一例可疑凝血病。
适用人群与场景
- 美国毒物中心2008年1月1日至2017年12月31日报告的单物质溴甲灵摄入并随访至已知医学结局的病例,共2674例。
- 儿童人群为2227例,年龄16天至12岁;成人人群为391例,年龄13至94岁。
红旗征与不能漏的情况
- 成人溴甲灵暴露中记录到癫痫发作、死亡及一例可疑凝血病。
- 成人故意摄入者中记录到1例死亡和4例严重效应;一例故意摄入死亡病例的细节提示可能误编码为长效抗凝血灭鼠剂。
研究设计与关键结果
- 研究类型为回顾性观察研究,数据来自美国国家毒物数据系统(NPDS),共纳入2674例单物质溴甲灵摄入并随访至已知医学结局的暴露。
- 儿童(16天至12岁)2227例中,无效应2143例(96.38%),轻微效应74例(3.32%),中度效应10例(0.45%),无严重临床效应或死亡。
- 成人(13至94岁)391例中,无效应257例(65.73%),轻微效应100例(25.58%),中度效应23例(5.88%),严重效应9例(2.30%),死亡2例(0.51%)。
- 成人故意摄入者中,死亡1例(0.25%),严重效应4例(1.02%);一例故意摄入死亡病例的细节提示可能误编码为长效抗凝血灭鼠剂。
证据类型、等级与局限
- 证据类型为回顾性观察研究,基于美国毒物中心国家毒物数据系统(NPDS)。
- 局限:原文自述数据集存在回顾性性质、依赖来电信息、选择偏倚、信息偏倚和编码错误。
- 局限:原文指出可能有一或两例归因于溴甲灵的死亡并非由溴甲灵所致。
对床旁实践的改变
- 儿童溴甲灵暴露未见严重效应或死亡,成人暴露多数无或轻微效应,但临床仍需注意成人故意摄入者中记录到的癫痫发作、死亡及一例可疑凝血病。
- 作者指出该数据集存在回顾性、依赖来电信息、选择偏倚、信息偏倚和编码错误等局限,且可能有一或两例归因于溴甲灵的死亡并非由溴甲灵所致。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Exposures to bromethalin rodenticides have increased since restrictions were placed on long acting anticoagulant rodenticide (LAAR) registrations in 2008. Bromethalin works, in part, by uncoupling mitochondrial oxidative phosphorylation. Toxicity in humans is not well characterized and no antidote is available. Methods: This retrospective observational study analyzed data from the National Poison Data System (NPDS). The data set was derived from single substance bromethalin ingestions followed to a known medical outcome that were reported to US poison centers from 01/01/2008 to 12/31/2017. Results: There were 2674 bromethalin exposures in the NPDS database that met inclusion criteria. Of these exposures 2227 (83.28%) were pediatric, aged 16 days-12 years. Within this population, no effects were seen in 2143 (96.38%) of the exposures, 74 (3.32%) had minor effects, and 10 (0.45%) had moderate effects. No major clinical effects or deaths occurred in pediatric patients, although one patient with a major effect was of unknown age. Exposures in patients >12 years encompassed 391 patients aged 13-94 years. No effect was seen amongst 257 (65.73%) of the patients, 100 (25.58%) had minor effects, 23 (5.88%) had moderate effects, nine (2.30%) had major effects, and two (0.51%) patients died. Intentional ingestions among these patients accounted for one (0.25%) death and four (1.02%) major effects. Case details of the intentional ingestion death suggest the possibility of a miscoded long acting coagulant rodenticide. Conclusions: No major effects or deaths were seen in pediatric exposures. A majority of the possible bromethalin exposures involving adults reported to poison centers resulted in minor or no effects, though seizures, death and one questionable case of coagulopathy were documented. This dataset suffers from its retrospective nature, reliance on caller information, selection bias, information bias, and miscoding. It is possible that one or both deaths attributed to bromethalin exposure were not actually due to bromethalin.
参考来源
- Feldman R, Stanton M, Borys D, et al. Medical outcomes of bromethalin rodenticide exposures reported to US poison centers after federal restriction of anticoagulants. Clin Toxicol (Phila). 2019. PMID: 30892957. doi:10.1080/15563650.2019.1582776
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。